BIOMAT Database Logo BIOMAT Database Logo

[Effect of treatment with recombinant erythropoietin in patients with multiple myeloma and kidney failure]. 1997

I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
I.interní klinika 1.lékarské fakulty Univerzity Karlovy a Vseobecné fakultní nemocnice v Praze, Praha, Czech Republic.

The efficacy of recombinant human erythropoietin (r-HuEPO) in patients with multiple myeloma (MM) has been confirmed in several clinical trials. We report our experience of r-HuEPO treatment in 5 myeloma patients with renal failure. The therapy with r-HuEPO (Eprex, Janssen-Cilag or Recormon, Boehringer, Mannheim) was started after 4-8 months from diagnosis, the drug was administered intravenously (in one patient subcutaneously after cessation of hemodialysis treatment), two or three times weekly. The initial doses were 4-12,000 units/week (mean 8,400). In all patients good response during the first month of therapy was observed. Median Hb and hematocrit increased from 70 g/l and 20.8% to 87 g/l and 26% after 1 month and to 105 g/l and 30.3% after 4-6 months, respectively. The need for blood transfusion decreased significantly--from 2.72 TU/month to 0.13 TU/month. WHO performance status and patients self-assessment of quality of live improved substantially after r-HuEPO. No serious adverse events, including hypertension and/or thromboembolic events were observed. In accordance with some previous reports we conclude r-HuEPO is effective and safe treatment in patients with MM and renal failure. Moreover, lower doses of growth factor could be effective in this particular group of patients.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004921 Erythropoietin Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.
D005260 Female Females
D006400 Hematocrit The volume of packed RED BLOOD CELLS in a blood specimen. The volume is measured by centrifugation in a tube with graduated markings, or with automated blood cell counters. It is an indicator of erythrocyte status in disease. For example, ANEMIA shows a low value; POLYCYTHEMIA, a high value. Erythrocyte Volume, Packed,Packed Red-Cell Volume,Erythrocyte Volumes, Packed,Hematocrits,Packed Erythrocyte Volume,Packed Erythrocyte Volumes,Packed Red Cell Volume,Packed Red-Cell Volumes,Red-Cell Volume, Packed,Red-Cell Volumes, Packed,Volume, Packed Erythrocyte,Volume, Packed Red-Cell,Volumes, Packed Erythrocyte,Volumes, Packed Red-Cell
D006454 Hemoglobins The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements. Eryhem,Ferrous Hemoglobin,Hemoglobin,Hemoglobin, Ferrous
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
[Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
April 1995, Anales de medicina interna (Madrid, Spain : 1984),
I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
[Effect of recombinant human erythropoietin on hepcidin mRNA expression in patients with multiple myeloma].
April 2011, Zhongguo shi yan xue ye xue za zhi,
I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia.
January 1997, Acta haematologica,
I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
Safety and efficacy of recombinant human erythropoietin treatment of anaemia associated with multiple myeloma in haemodialysed patients.
January 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
[Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma].
July 1996, Casopis lekaru ceskych,
I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
[Human recombinant erythropoietin in the treatment of the anemia of multiple myeloma].
November 1997, Anales de medicina interna (Madrid, Spain : 1984),
I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
Effective treatment of the anaemia associated with multiple myeloma by recombinant human erythropoietin.
January 1991, Clinical and laboratory haematology,
I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
[Treatment of multiple myeloma associated anemia with human recombinant erythropoietin in a hemodialysis patient].
January 1995, Polskie Archiwum Medycyny Wewnetrznej,
I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma.
January 2007, Acta haematologica,
I Spicka, and F Svára, and L Novosadová, and I Mácel, and V Válková, and S Sulková, and M Merta, and P Klener
Recombinant human erythropoietin and the anemia of multiple myeloma.
March 1993, Stem cells (Dayton, Ohio),
Copied contents to your clipboard!